03-05-2023 : 769 Pharmacists work as Medical Representative, of which 39 work as Senior Medical Representative * 02-06-2020 : 216 non Pharmacists work as Medical Representative, and 54 work as Senior Medical Representative * 05-06-2023 : In Lebanon, 88 generic medicinal products are more expensive than their Originators * 31-12-2019 : A medicinal product refused in Europe is marketed in Lebanon * 05-06-2023 : At least 332 medicinal products are available on the Lebanese market and are not available in the country of origin * 05-06-2023 : The price of the most expensive medicine available in Lebanon is 30434557 LL * 05-06-2023 : At least 1309 medicinal products are more expensive in Lebanon than in the countries of origin * 01-01-2019 : Daktavira, a generic of Daklinza, is registered in Lebanon but has no public price * 31-12-2019 : 352 medicinal products have been declared as non-marketed or withdrawn * 09-11-2021 : 64.72% of lebanese pharmacists are female * 31-12-2019 : 486 medicines were submitted to the Ministry of Health for a marketing authorization, and 514 medicines were registered to date * 15-06-2018 : The Minister of Public Health, has decided to suspend the commercialization of AB Slim (Ab Care Medical Herbs), which contains sibutramine, sildenafil and phenolphthalein * 01-06-2020 : Some Non-Marketed medicines are still imported * 01-06-2020 : Ixempra, a medicinal product withdrawn in Europe is imported to lebanon * 01-06-2020 : A vaccine made in India, removed from WHO list of prequalified vaccines, is submitted for registration in Lebanon * 01-06-2020 : Lebanon has 14 CROs, and is ranked as one of the largest countries in the world in clinical studies. According to the WHO, 817 clinical studies are currently conducted in Lebanon. * 05-01-2021 : * 01-10-2023 : Adakveo is now withdrawn from use in the European Union due to lack of therapeutic efficacy *
Trazimera 150mg : | |
Type | Medicine Authorised |
Originator | Biotech (Trazimera 150mg) |
Agent | Food & Drug Corporation |
Distributor | Food & Drug Corporation |
Laboratory | Pfizer |
Responsible Party | Pfizer Canada ULC |
Origin | Canada |
Manufacturer | Pfizer Manufacturing Belgium NV |
Origin | Belgium |
ATC | L01XC03 |
Trazimera 150mg :
Trazimera 150mg :
Trazimera 150mg :
Trazimera 150mg :
Trazimera 150mg :
Hazard Level |
---|
◼ Major |
◼ Moderate |
◼ Minor |
◼ Safe |
Trazimera 150mg :
Frequency | Percentage |
---|---|
Very Common | ≥ 1/10 |
Common | ≥ 1/100 - < 1/10 |
Uncommon | ≥ 1/1,000 - < 1/100 |
Rare | ≥ 1/10,000 - < 1/1,000 |
Very Rare | < 1/10,000 |
Unknown | Cannot be Estimated |
Effect | Frequency |
---|---|
Abdominal pain | Very Common |
Acne | Common |
Acute pulmonary oedema | Not known |
Acute respiratory distress syndrome | Not known |
Alopecia | Very Common |
Anaemia | Very Common |
Anaphylactic reactions | Rare |
Anaphylactic shock | Rare |
Angioedema (Angioneurotic oedema) (Quincke oedema) | Not known |
Anorexia | Very Common |
Anxiety | Common |
Arrhythmia | Very Common |
Arthralgia (Pain joint) (Joint ache) | Very Common |
Arthritis | Common |
Asthenia | Very Common |
Asthma | Common |
Autoimmune thrombocytopenia | Not known |
Back pain | Common |
Blood pressure decreased | Very Common |
Blood pressure increased | Very Common |
Bone pain | Common |
Bronchospasm | Not known |
Cardiac flutter | Very Common |
Cardiogenic shock | Not known |
Cardiomyopathy | Common |
Chest pain | Very Common |
Chills | Very Common |
Congestive cardiac failure aggravated | Common |
Conjunctivitis | Very Common |
Constipation | Very Common |
Contusion | Common |
Cough | Very Common |
Cystitis | Common |
Deafness | Uncommon |
Depression | Common |
Dermatitis | Common |
Diarrhoea (Diarrhea) | Very Common |
Dizziness | Very Common |
Dry eye | Common |
Dry mouth (Xerostomia) | Common |
Dry skin | Common |
Dysguesia (taste perversion) (Taste abnormality) (Taste disturbance) | Very Common |
Dyspepsia | Very Common |
Dyspnoea (dyspnea) | Very Common |
Ecchymosis | Common |
Ejection fraction decreased | Very Common |
Epistaxis (Nasal bleeding) | Very Common |
Erythema | Very Common |
Fatigue | Very Common |
Febrile neutropenia (Neutropenic fever) | Very Common |
Gallop rhythm present | Not known |
Glomerulonephritis membranous | Not known |
Glomerulonephropathy | Not known |
Haemorrhoids | Common |
Hand and foot syndrome (Palmar-plantar erythrodysaesthesia syndrome) | Very Common |
Headache | Very Common |
Hepatitis | Common |
Hepatocellular injury | Common |
Hot flush | Very Common |
Hyperhidrosis | Common |
Hyperkalaemia | Not known |
Hypersensitivity | Common |
Hypertonia | Common |
Hypoprothrombinaemia | Not known |
Hypotension | Common |
Hypoxia | Not known |
Infection | Very Common |
Influenza | Common |
Influenza-like symptoms | Very Common |
Infusion related reaction | Very Common |
Insomnia | Very Common |
Interstitial lung disease | Not known |
Jaundice | Rare |
Lacrimation increased (Epiphora) | Very Common |
Laryngeal oedema | Not known |
Leucopenia (Leukopenia) | Very Common |
Lip swelling | Very Common |
Liver tenderness | Common |
Lung disorder | Common |
Lung infiltration (pulmonary infiltration) | Not known |
Maculopapular rash | Common |
Malaise | Common |
Malignant neoplasm progression | Not known |
Mastitis (breast inflammation) | Common |
Mucosal inflammation | Very Common |
Muscle spasms | Common |
Muscle tightness | Very Common |
Myalgia | Very Common |
Nail disorders | Very Common |
Nasopharyngitis | Very Common |
Neck pain | Common |
Neoplasm progression | Not known |
Neutropenic sepsis | Common |
Oedema | Common |
Oedema peripheral | Very Common |
Oligohydramnios | Not known |
Onychoclasis | Common |
Orthopnoea | Not known |
Oxygen saturation decreased | Not known |
Pain | Very Common |
Pain in extremity (Pain in limb) | Common |
Palpitations | Common |
Papilloedema | Not known |
Paraesthesia (paresthesia) | Very Common |
Pericardial effusion | Uncommon |
Peripheral neuropathy aggravated | Common |
Pharyngitis | Common |
Pleural effusion | Common |
Pneumonia | Common |
Pneumonitis | Uncommon |
Pruritus | Common |
Pulmonary fibrosis | Not known |
Pulmonary hypoplasia | Not known |
Pulmonary oedema | Not known |
Pyrexia | Very Common |
Renal disorder | Common |
Renal failure | Not known |
Renal hypoplasia | Not known |
Respiratory distress | Not known |
Respiratory failure | Not known |
Retinal haemorrhage | Not known |
Rhinitis | Common |
Rhinorrhoea | Very Common |
Sinusitis | Common |
Skin infection | Common |
Skin rash | Very Common |
Somnolence | Common |
Stomatitis | Very Common |
Supraventricular tachyarrhythmia | Common |
Swelling face | Very Common |
Thrombocytopenia (Thrombopenia) | Very Common |
Tremor | Very Common |
Tumour lysis syndrome | Not known |
Upper respiratory tract infection | Common |
Urinary tract infection | Common |
Urticaria | Uncommon |
Vasodilation | Common |
Vomiting | Very Common |
Weight decreased (Weight loss) | Very Common |
Wheezing | Uncommon |
White blood cell count decreased | Very Common |
Trazimera 150mg :
▲ Most Expensive |
▼ Least Expensive |
P.P. = | Public Price |
P/U = | Price Per Unit |
- Products with same active ingredients |
- Products with same strength |
- Products with same route of administration |
NB : Products With Same Indication |
Different Units By MoH Code
Trazimera 150mg MoH 10211 :
Form | Powder for concentrate for solution for infusion |
Packaging | Vial (Type I Glass) |
Package Size | Box of 1 |
Package Content | 15 mL clear glass type I vial with butyl rubber stopper laminated with a fluoro-resin film |
Strength | 150mg |
Storage Condition | 2-8°C protect from light |
Public Price | 11914704.44 L.L. |
Stratum | D |
NSSF | ✘ |
Quarantine | ✘ |
Reg. Number | 38120/1 |
Submission date | 11/03/2020 |
Registration Year | 23/07/2020 |
Price Comparison
● Country: | Finland | |
● Package Size: | 150mg | |
● Public Price: | 849.66 EUR | ( 82,311,662.16 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 849,66 EUR | ( 82,247,724.00 LBP ) |
● Reference: | Kela | |
● Pricing Date: | 22/04/2021 | |
● Type: | Medicine Authorised |
● Country: | Germany | |
● Package Size: | 1 | |
● Public Price: | 766.96 EUR | ( 74,300,016.96 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 766,96 EUR | ( 74,207,016.00 LBP ) |
● Pricing Date: | 24/10/2020 | |
● Type: | Medicine Authorised |
● Country: | Iceland | |
● Package Size: | 1 | |
● Public Price: | 109962 ISK | ( 70,925,490.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 109962 ISK | ( 70,925,490.00 LBP ) |
● Pharmacy Price: | 84415 ISK | ( 54447675 LBP ) |
● Reference: | Icelandic Medicines Agency | |
● Pricing Date: | 01/04/2020 | |
● Type: | Medicine Authorised |
● Country: | Denmark | |
● Package Size: | 1 stk. | |
● Public Price: | 5197.45 DKK | ( 67,442,111.20 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 5197,45 DKK | ( 67,436,272.00 LBP ) |
● Pharmacy Price: | 3859.21 DKK | ( 50077108.96 LBP ) |
● Reference: | Danish Medicine Agency | |
● Pricing Date: | 19/05/2021 | |
● Type: | Medicine Authorised |
● Country: | Switzerland | |
● Package Size: | 1 | |
● Public Price: | 562.45 CHF | ( 58,168,579.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 562,45 CHF | ( 58,122,040.00 LBP ) |
● Exfactory Price: | 475.67 CHF | |
● Pricing Date: | 04/04/2021 | |
● Type: | Medicine Authorised |
● Country: | Norway | |
● Package Size: | x150mg | |
● Public Price: | 6169.5 NOK | ( 49,997,628.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 6169,5 NOK | ( 49,993,576.00 LBP ) |
● Pharmacy Price: | 4786.89 NOK | ( 38792956.56 LBP ) |
● Reference: | Norwegian Medicine Agency | |
● Pricing Date: | 01/04/2020 | |
● Type: | Medicine Authorised |
● Country: | UK | |
● Package Size: | 1 | |
● Public Price: | 366.66 GBP | ( 41,670,542.34 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 366,66 GBP | ( 41,595,534.00 LBP ) |
● Reference: | DMD | |
● Pricing Date: | 08/03/2021 | |
● Type: | Medicine Authorised |
● Country: | Greece | |
● Package Size: | 1 | |
● Public Price: | 406.06 EUR | ( 39,337,468.56 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 406,06 EUR | ( 39,331,656.00 LBP ) |
● Exfactory Price: | 343.1 EUR | |
● Pharmacy Price: | 348.25 EUR | ( 33737067 LBP ) |
● Reference: | National Organization for Medicines | |
● Pricing Date: | 25/02/2021 | |
● Type: | Medicine Authorised |
● Country: | Belgium | |
● Package Size: | 1 | |
● Public Price: | 345 EUR | ( 33,422,220.00 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 345 EUR | ( 33,422,220.00 LBP ) |
● Reference: | cbip | |
● Pricing Date: | 02/12/2020 | |
● Type: | Medicine Authorised |
● Country: | Lebanon | |
● Form: | Powder for concentrate for solution for infusion | |
● Package Size: | Box of 1 | |
● Public Price: | 11914704.44 LBP | ( 11,914,704.44 LBP ) |
● Pack size unit used: | 1 | |
● Cost/Unit: | 11914704,44 LBP | ( 11,914,704.00 LBP ) |
● Pricing Date: | 13/06/2024 |
● Country: | Spain |
● Package Size: | 1 vial de 15 ml |
● Reference: | Agencia Española de Medicamentos y Productos Sanitarios |
● Pricing Date: | 06/05/2021 |
● Type: | Medicine Authorised |
● Country: | France |
● Package Size: | 1 |
● Reference: | ansm |
● Pricing Date: | 15/05/2021 |
● Type: | Medicine Authorised |
Note
You have to register to view this info
Drop File